Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid

Narrative Review of Cannabidiol as an Antipsychotic and Recommendations for Legal Regulations

Walkey, Lisa Rachel Lena BEng, MASc, MD; Tanguay, Robert L. BSc (Hons), MD, FRCPC, CCSAM, CISAM; el-Guebaly, Nady MD, FRCPC, DABAM

Author Information
The Canadian Journal of Addiction: September 2018 - Volume 9 - Issue 3 - p 23-29
doi: 10.1097/CXA.0000000000000026



In the article that appeared on pages 23–29 of the Canadian Journal of Addiction September 2018 issue, the disclosures of Robert Tanguay were not provided in the journal, and they are:

• Relationships with financial interests:

Grants/Research Support: Canopy, Otsuka, Pfizer, Perdue, Shire, Jansen, Sunovion, Lundbeck, Allergan

Speakers Bureau/Honoraria: Indivior, Canopy, Pfizer, Otsuka, Lundbeck

Consulting Fees: Lundbeck, Indivior, Allergan

Other: Independent CME - MD Briefcase Independent CME; Owner- RLT Conferences; Private- PFSP, CPSA, ABVMA, City of Calgary, Gov’t of Ab, ASEBP, Shell, Insurance Companies, Law Firms

The omission was not discovered until after the article published in the issue. The journal regrets this error.

Canadian Journal of Addiction. 9(4):24, December 2018.

Copyright © 2018 by the Canadian Society of Addiction Medicine